AEON Biopharma shares surge 17.23% premarket after FDA meeting validates biosimilar strategy and financing reduces debt.

AEON Biopharma surged 17.23% in premarket trading following the announcement of positive initial comparative analytical results for its ABP-450 biosimilar to BOTOX, including a 100% amino acid sequence match and favorable functional similarity. The company also reported constructive feedback from the FDA following a Type 2a meeting, validating its biosimilar strategy. Additionally, AEON completed a $6 million PIPE financing and a debt exchange, reducing outstanding obligations by over 90%, while appointing John Bencich as CFO to strengthen financial leadership. These developments, signaling regulatory progress and improved financial stability, reinforced investor confidence in the firm’s path toward U.S. market entry for ABP-450.